IR@PKUHSC  > 北京大学深圳医院  > 检验科
学科主题临床医学
Vaginal Nystatin Versus Oral Fluconazole for the Treatment for Recurrent Vulvovaginal Candidiasis
Fan, Shangrong1,2; Liu, Xiaoping3; Wu, Cong1; Xu, Lixuan1; Li, Jianling1
关键词Recurrent Vulvovaginal Candidiasis Candida Antifungal Susceptibility Nystatin Fluconazole
刊名MYCOPATHOLOGIA
2015-02-01
DOI10.1007/s11046-014-9827-4
179期:1-2页:95-101
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Mycology
研究领域[WOS]Mycology
关键词[WOS]ANTIFUNGAL SUSCEPTIBILITIES ; SOUTHERN CHINA ; VAGINITIS ; THERAPY ; CANDIDOSIS ; GUIDELINES ; MANAGEMENT ; WOMEN
英文摘要

Recurrent vulvovaginal candidiasis (RVVC) is a common condition that can physically and psychologically impact patients. We compared the efficacy and safety of vaginal nystatin suppositories for 14 days each month versus standard oral fluconazole regimens for the treatment for RVVC. Patients (n = 293) were enrolled in the study from April 2010 to September 2013. After the initial therapy, the mycological cure rates were 78.3 % (119/152) and 73.8 % (104/141) in the nystatin group and fluconazole group, respectively (95 % CI, 0.749-2.197, p > 0.05). The mycological cure rates at the end of maintenance therapy were 80.7 % (96/119) and 72.7 % (72/99) in the two groups, respectively (95 % CI, 0.954-3.293, p > 0.05).The mycological cure rates at the end without treatment for 6 months were 81.25 % (78/96) and 82.19 % (60/73) in the two groups, respectively (95 % CI, 0.427-2.066, p > 0.05). The mycological cure rates of RVVC caused by C. albicans were 84.0 % (89/106) and 81.8 % (99/121) in the two groups, respectively. The mycological cure rates of RVVC caused by C. glabrata were 64.3 % (27/42) and 12.5 % (2/16) in the two groups, respectively. The initial and 6-month maintenance therapy were successful in five of the nine patients in the nystatin group with RVVC caused by fluconazole-resistant Candida, whereas in the fluconazole group, initial therapy failed in all patients with RVVC caused by fluconazole-resistant Candida (n = 7). We conclude that both fluconazole and nystatin therapies are effective in treating RVVC. Nystatin may also be effective for the treatment for RVVC caused by C. glabrata or fluconazole-resistant Candida.

语种英语
WOS记录号WOS:000349528700011
项目编号201201001
资助机构Shenzhen Science and Technology
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/50570
专题北京大学深圳医院_检验科
作者单位1.Peking Univ Shenzhen Hosp, Dept Obstet & Gynaecol, Shenzhen 518036, Peoples R China
2.Shenzhen Key Lab Gynecol Diagnost Technol Res, Shenzhen 518036, Peoples R China
3.Peking Univ Shenzhen Hosp, Dept Lab Sci, Shenzhen 518036, Peoples R China
推荐引用方式
GB/T 7714
Fan, Shangrong,Liu, Xiaoping,Wu, Cong,et al. Vaginal Nystatin Versus Oral Fluconazole for the Treatment for Recurrent Vulvovaginal Candidiasis[J]. MYCOPATHOLOGIA,2015,179(1-2):95-101.
APA Fan, Shangrong,Liu, Xiaoping,Wu, Cong,Xu, Lixuan,&Li, Jianling.(2015).Vaginal Nystatin Versus Oral Fluconazole for the Treatment for Recurrent Vulvovaginal Candidiasis.MYCOPATHOLOGIA,179(1-2),95-101.
MLA Fan, Shangrong,et al."Vaginal Nystatin Versus Oral Fluconazole for the Treatment for Recurrent Vulvovaginal Candidiasis".MYCOPATHOLOGIA 179.1-2(2015):95-101.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Fan, Shangrong]的文章
[Liu, Xiaoping]的文章
[Wu, Cong]的文章
百度学术
百度学术中相似的文章
[Fan, Shangrong]的文章
[Liu, Xiaoping]的文章
[Wu, Cong]的文章
必应学术
必应学术中相似的文章
[Fan, Shangrong]的文章
[Liu, Xiaoping]的文章
[Wu, Cong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。